Using Real-World Evidence to Assess Hepatotoxicity of Biologics
July 6, 2023
A real-world evidence (RWE) study published in Nature Scientific Reports assessed the hepatotoxicity of several major biologics, such as adalimumab, trastuzumab, IF-Beta 1a, and insulin glargine. The study, which used real-world data (RWD) from over 2 million patients, found that many of these key biologics have some degree of hepatoxicity.
According to the authors, “The real-world data obtained through multiple sources which are related to patient health status and behavior in routine clinical practice can give deeper insights into drug safety and efficacy. The RWE -based analysis revealed a statistically significant link between biologics usage and hepatotoxicity in patients. Hepatotoxicity induced by biological agents is a novel emerging cause of drug-induced liver injury (DILI).”
To read more, click here.
(Source: Nature, July 5th, 2023)
